Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631387 | 0.91 | MPO (0.51) | KCNMA1MPOCYP19A1HRH4NPC1 | |
| SCHEMBL18080404 | 0.89 | KCNMA1 (0.52) | KCNMA1MPOCYP19A1HRH4HRH3 | |
| SCHEMBL18081748 | 0.83 | EP300 (0.40) | CYP19A1EP300 | |
| SCHEMBL16631733 | 0.81 | CYP19A1 (0.51) | CYP19A1NPC1RAB9A | |
| SCHEMBL18080369 | 0.81 | MPO (0.48) | KCNMA1MPOCYP19A1HRH4NPC1 | |
| SCHEMBL16631911 | 0.79 | KCNMA1 (0.46) | KCNMA1HRH4HRH3 | |
| SCHEMBL18081911 | 0.78 | EP300 (0.38) | MPOEP300 | |
| SCHEMBL16631915 | 0.78 | KCNMA1 (0.55) | KCNMA1MPOCYP19A1HRH4HRH3 | |
| SCHEMBL16631917 | 0.77 | DPP4 (0.35) | EP300 | |
| SCHEMBL16631734 | 0.77 | NTRK1 (0.31) | EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | KCNMA1 4287/4885MPO 2859/4885CYP19A1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.